Dandelion Health has partnered with InVision Medical Technology to enhance cardiac data collection in life sciences, enabling companies to access significantly more cardiac measurements per patient.
This collaboration aims to leverage AI technology to analyze echocardiogram data, producing up to 30 times more cardiac metrics than traditionally recorded. Dandelion Health's platform will integrate InVision's echocardiography AI, which interprets raw imaging data to generate detailed insights and risk assessments that were previously unavailable in standard clinical care. By combining this enhanced data with over a decade of real-world patient records, researchers can conduct more precise studies in areas such as heart failure and cardiometabolic diseases.
The partnership addresses a critical gap in cardiac imaging, where only relevant measurements are typically extracted for immediate diagnosis. InVision's technology standardizes measurements across various echocardiograms, reducing variability and enhancing the reliability of research outcomes. This consistency is crucial for accurately assessing treatment effects and improving clinical trial designs.
As the landscape of cardiometabolic therapies evolves, this partnership provides an innovative approach for life sciences companies. By utilizing comprehensive cardiac data, researchers can better phenotype patients and assess treatment impacts, ultimately accelerating the development of new therapies and improving patient outcomes.